Skip to main content

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic DMARDs

    Basic Details
    Reagan-Udall Foundation

    Individuals with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), compared with non-RA populations based on several recent studies. However, information is sparse on the risk of VTE among patients receiving treatment with specific disease-modifying antirheumatic drugs (DMARDs) or categories of therapies. The objective was to estimate the incidence of VTE among patients receiving routine clinical care for RA, specifically during treatment with conventional (c) and biologic (b) DMARDs. Incidence rates were estimated in a retrospective cohort study of patients with RA (defined as at least two International Classification of Disease, Ninth Revision, Clinical Modification [ICD-9-CM] Diagnostic codes) enrolled in US health insurance plans between October 1, 2010 to September 30, 2015 and participating in the Innovation in Medical Evidence Development and Surveillance (IMEDS) program. These data are formatted into the U.S. Food and Drug Administration’s Sentinel Common Data Model and Sentinel’s publicly available standardized analysis tools were used to estimate the incidence rates of VTE following initiation of cDMARDs or bDMARDs. 


    Judith C. Maro, Talia Menzin, Kenneth Hornbuckle, Jon T. Giles, Arthur Kavanaugh, Thomas Dörner, David Martin, Ting-Ying Huang, Claudia A. Salinas